AXIM Biotechnologies, Inc. (AXIM)

Market Cap	3.41M
Revenue (ttm)	39,766
Net Income (ttm)	-10.05M
Shares Out	278.43M
EPS (ttm)	-0.05
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,051,159
Open	0.0105
Previous Close	0.0103
Day's Range	0.0094 - 0.0133
52-Week Range	0.0090 - 0.0400
Beta	1.40
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About AXIM

AXIM Biotechnologies, Inc. develops and sells diagnostic healthcare solutions in the areas of SARS-CoV-2, eye health, and other diseases. The company is developing tests for dye eye diseases; SARS-CoV-2 neutralizing antibody tests; and fentanyl neutralizing antibody tests. It also developing a line of novel diagnostics for early cancer detection, response to treatment, and recurrence monitoring. The company was formerly known as Axim International Inc. and changed its name to AXIM Biotechnologies, Inc. in July 2014. AXIM Biotechnologies, Inc. w...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2010
• Employees: 6
• Stock Exchange: OTCMKTS
• Ticker Symbol: AXIM

Financial Performance

In 2023, AXIM's revenue was $39,518, an increase of 345.27% compared to the previous year's $8,875. Losses were -$8.06 million, 35.3% more than in 2022.